Patents Assigned to NRL Pharma, Inc.
  • Publication number: 20230001041
    Abstract: Provided is a method for preventing the disturbance of vaginal bacterial flora during the menstrual period and improving the vaginal bacterial flora. One aspect of the present invention is a sanitary product carrying lactoferrin or a composition comprising lactoferrin and an auxiliary substance. Also provided is a kit comprising a sanitary product, and lactoferrin or the composition comprising lactoferrin and an auxiliary substance.
    Type: Application
    Filed: January 25, 2021
    Publication date: January 5, 2023
    Applicants: NRL Pharma, Inc., Varinos, INC.
    Inventors: Yoshiyuki Sakuraba, Yoko Nagai, Tatsuo Hoshino, Megumi Ohno
  • Publication number: 20220040270
    Abstract: The purpose of the present invention is to provide an agent for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora has been improved or normalized. An aspect of the present invention is an agent for improving intrauterine bacterial flora that contains lactoferrin or a salt thereof as an active ingredient. Additionally provided are: an agent or composition for improving intrauterine flora or treating or preventing diseases caused by the imbalance of intrauterine bacterial flora, the agent or composition containing lactoferrin or a salt thereof; a method for treating or preventing diseases caused by imbalance of intrauterine bacterial flora, the method comprising administrating the agent or composition; and a method for determining whether intrauterine bacterial flora has been improved or normalized.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 10, 2022
    Applicants: NRL Pharma, Inc., Varinos, INC.
    Inventors: Tatsuo Hoshino, Yoshiyuki Sakuraba, Yoko Nagai, Koichi Kyono, Tomoko Hashimoto
  • Patent number: 10562959
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or(Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 18, 2020
    Assignee: NRL PHARMA, INC.
    Inventors: Atsushi Sato, Shinji Kagaya
  • Publication number: 20190309049
    Abstract: The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 10, 2019
    Applicant: NRL PHARMA, INC.
    Inventors: Atsushi SATO, Shinji KAGAYA
  • Publication number: 20180072794
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 15, 2018
    Applicant: NRL PHARMA, INC.
    Inventors: Atsushi SATO, Shinji KAGAYA
  • Patent number: 9809641
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: November 7, 2017
    Assignee: NRL PHARMA, INC.
    Inventors: Atsushi Sato, Shinji Kagaya
  • Publication number: 20170296629
    Abstract: An object of the present invention is to provide a novel drug inhibiting extracellular trap formation in leukocytes. The present invention provides an inhibitor of extracellular trap formation in leukocytes containing a lactoferrin fragment, and a composition containing lactoferrin for treating a disease related to the extracellular trap formation in leukocytes.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 19, 2017
    Applicants: KEIO UNIVERSITY, NRL PHARMA, INC.
    Inventors: Junichi HIRAHASHI, Koshu OKUBO, Hiroshi KAWAKAMI, Shinji KAGAYA
  • Patent number: 8673839
    Abstract: A biologically active complex of lactoferrin with a branched non-peptide hydrophilic polymer, one example of which is represented by the following formula [1]: LF-[X-Lp-R—(Yp-POLY)q]n??[I] Wherein LF is lactoferrin, X is a linkage generated by reaction of functional groups, L is a linker, R is an aliphatic hydrocarbon group having at least 3 carbon atoms, Y is a heteroatom linkage, POLY is a non-peptide hydrophilic polymer, p is 0 or 1, q is an integer of 2 to 10, and n is an integer of 1 to 10.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: March 18, 2014
    Assignee: NRL Pharma, Inc.
    Inventors: Yasuhiro Nojima, Atsushi Sato
  • Patent number: 8399414
    Abstract: The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The composition of this invention is useful for treatment of at least one disease or condition selected from the group consisting of pains, including the phase 1 pain and the phase 2 pain, anxiety and stress. The composition is particularly beneficial to alleviating or getting rid of the pain and anxiety which significantly lower quality of life of patients with end-stage cancer. The composition of this invention is also useful for treatment of pains, including the phase 1 pain and the phase 2 pain, and inflammation which accompany arthritis or diseases in the junctions of bones (e.g. rheumatoid arthritis, osteoarthritis, frozen shoulder, sports injuries such as tennis elbow and baseball shoulder, and low back pain).
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: March 19, 2013
    Assignee: NRL Pharma, Inc.
    Inventors: Etsumori Harada, Takashi Takeuchi, Kenichiro Hayashida, Kunio Ando, Hirohiko Shimizu
  • Publication number: 20110009313
    Abstract: A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a para-nitrophenol leaving group, under conditions that allow formation of an amide group between the PEG derivative and the lactoferrin. A PEGylated lactoferrin complex contains a linear PEG or a modified product thereof covalently bonded to lactoferrin via an amide bond, and a pharmaceutical composition includes a PEGlyated lactoferrin complex, a therapeutically inert base, and/or an additive.
    Type: Application
    Filed: March 13, 2009
    Publication date: January 13, 2011
    Applicant: NRL PHARMA, INC.
    Inventor: Atsushi Sato
  • Patent number: 7629471
    Abstract: Ascochlorin or an analog or derivative thereof and a compound having a primary amino group are mixed and reacted with each other in the presence/absence of a basic catalyst to synthesize a novel imino compound. The novel imino compound thus synthesized is a ligand capable of activating nuclear receptor superfamily such as retinoid orphan receptor (RXR), peroxisome proliferator-activated receptor (PPAR) and steroid receptor (PXR), and shows an effect of promoting the transcription of a drug-metabolizing enzyme CYP7A1. The imino compound has a therapeutic effect on diseases such as lifestyle-related diseases, chronic inflammation and cancers.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: December 8, 2009
    Assignee: NRL Pharma, Inc.
    Inventors: Takeshi Kitahara, Hidenori Watanabe, Kunio Ando
  • Publication number: 20090281029
    Abstract: A biologically active complex of lactoferrin with a branched non-peptide hydrophilic polymer, one example of which is represented by the following formula [I]: LF-[X-Lp-R—(Yp-POLY)q]n ??[I] Wherein LF is lactoferrin, X is a linkage generated by reaction of functional groups, L is a linker, R is an aliphatic hydrocarbon group having at least 3 carbon atoms, Y is a heteroatom linkage, POLY is a non-peptide hydrophilic polymer, p is 0 or 1, q is an integer of 2 to 10, and n is an integer of 1 to 10.
    Type: Application
    Filed: August 22, 2006
    Publication date: November 12, 2009
    Applicant: NRL PHARMA, INC.
    Inventors: Yasuhiro Nojima, Atsushi Sato
  • Publication number: 20090082269
    Abstract: It is intended to provide a drug for ameliorating symptoms or diseases caused by heavy metals (for example, Wilson's disease, heavy metal toxication, aging, fulminant hepatitis and so on) which has a high safety without any fear of side effect, can eliminate heavy metals such as copper ion accumulated in excess in the living body to prevent or lessen the accumulation of the heavy metals in the living body, thereby eliminating or relieving the effects of the heavy metals; and compositions such as a medicinal composition, a food and a cosmetic containing the same. The drug and compositions as described above are characterized by containing lactoferrin and/or an active derivative of the same as the active ingredient.
    Type: Application
    Filed: June 27, 2006
    Publication date: March 26, 2009
    Applicant: NRL PHARMA, INC.
    Inventor: Akihito Tsubota
  • Patent number: 7432306
    Abstract: The present invention has an object to develop novel compounds which are effective for the therapy of syndrome X, cancer, myxedema, vascular chronic inflammation and the like, and furthermore prevent/treat the restenosis caused in an artery expansion by a balloon or a stent and have the activity facilitating regenerative medicine by inhibiting rejection of own cells or tissues to be transplanted and the method for preparing the same. Novel acetal derivatives obtained by acylating the hydroxyl group at the 2-position of the orcylaldehyde which ascochlorin and its analogs have and thereafter bonding an alcohol to the aldehyde group in the presence of a basic catalyst are found to achieve the object.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: October 7, 2008
    Assignee: NRL Pharma, Inc.
    Inventors: Takeshi Kitahara, Hidenori Watanabe, Kunio Ando
  • Publication number: 20070054966
    Abstract: The present invention has an object to develop novel compounds which are effective for the therapy of syndrome X, cancer, myxedema, vascular chronic inflammation and the like, and furthermore prevent/treat the restenosis caused in an artery expansion by a balloon or a stent and have the activity facilitating regenerative medicine by inhibiting rejection of own cells or tissues to be transplanted and the method for preparing the same. Novel acetal derivatives obtained by acylating the hydroxyl group at the 2-position of the orcylaldehyde which ascochlorin and its analogs have and thereafter bonding an alcohol to the aldehyde group in the presence of a basic catalyst are found to achieve the object.
    Type: Application
    Filed: September 7, 2005
    Publication date: March 8, 2007
    Applicant: NRL PHARMA, INC.
    Inventors: Takeshi Kitahara, Hidenori Watanabe, Kunio Ando